Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Although recent clinical trials targeting amyloid-β in Alzheimer’s disease have shown promising results, there is increasing evidence suggesting that understanding alternative disease pathways that interact with amyloid-β metabolism and amyloid pathology might be important to halt the clinical deterioration. In particular, there is evidence supporting a critical role of astroglial activation and astrocytosis in Alzheimer’s disease. However, so far, no studies have assessed whether astrocytosis is independently related to either amyloid-β or tau pathology in vivo. To address this question, we determined the levels of the astrocytic marker GFAP in plasma and CSF of 217 amyloid-β-negative cognitively unimpaired individuals, 71 amyloid-β-positive cognitively unimpaired individuals, 78 amyloid-β-positive cognitively impaired individuals, 63 amyloid-β-negative cognitively impaired individuals and 75 patients with a non-Alzheimer’s disease neurodegenerative disorder from the Swedish BioFINDER-2 study. Participants underwent longitudinal amyloid-β (18F-flutemetamol) and tau (18F-RO948) PET as well as cognitive testing. We found that plasma GFAP concentration was significantly increased in all amyloid-β-positive groups compared with participants without amyloid-β pathology (P < 0.01). In addition, there were significant associations between plasma GFAP with higher amyloid-β-PET signal in all amyloid-β-positive groups, but also in cognitively normal individuals with normal amyloid-β values (P < 0.001), which remained significant after controlling for tau-PET signal. Furthermore, plasma GFAP could predict amyloid-β-PET positivity with an area under the curve of 0.76, which was greater than the performance achieved by CSF GFAP (0.69) and other glial markers (CSF YKL-40: 0.64, soluble TREM2: 0.71). Although correlations were also observed between tau-PET and plasma GFAP, these were no longer significant after controlling for amyloid-β-PET. In contrast to plasma GFAP, CSF GFAP concentration was significantly increased in non-Alzheimer’s disease patients compared to other groups (P < 0.05) and correlated with amyloid-β-PET only in amyloid-β-positive cognitively impaired individuals (P = 0.005). Finally, plasma GFAP was associated with both longitudinal amyloid-β-PET and cognitive decline, and mediated the effect of amyloid-β-PET on tau-PET burden, suggesting that astrocytosis secondary to amyloid-β aggregation might promote tau accumulation. Altogether, these findings indicate that plasma GFAP is an early marker associated with brain amyloid-β pathology but not tau aggregation, even in cognitively normal individuals with a normal amyloid-β status. This suggests that plasma GFAP should be incorporated in current hypothetical models of Alzheimer’s disease pathogenesis and be used as a non-invasive and accessible tool to detect early astrocytosis secondary to amyloid-β pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, blood measures of p-tau181, p-tau217, p-tau231, glial fibrillary acid protein (GFAP), neurofilament light (NfL) and Aβ42/40 have been shown to change in preclinical AD and can discriminate this state from CU individuals with non-AD pathological changes1,3,6–13.”
From Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease (2022) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased GFAP, associated with astrogliosis, is a hallmark of and linked to pathological processes in Alzheimer’s disease, particularly amyloid build-up, and neuroinflammation [27].”
From Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer’s disease (2026) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For GFAP we observed more pronounced group differences in blood than in CSF, as has also been observed by other groups [33, 75].”
In the citing paper
“Elevated levels of GFAP in plasma and serum are associated with the degree and rate of neurodegeneration, Aβ positivity and cognitive decline in individuals with AD [27, 28].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 2×
“There is increasing evidence suggesting that the pathogenesis of Alzheimer’s disease is not restricted to amyloid-b plaques and tau tangles but also includes strong interactions with immunological mechanisms.(1) In line with this, astrocyte reactivity or astrocytosis is a well-known pathological process that is common…”
BackgroundMethodJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 5×
“Plasma and CSF samples were collected in the morning during the same visit, with participants non-fasting.(40) Blood was collected in six EDTA-plasma tubes and centrifuged (2000g, + 4 C for 10 min).”
MethodInfluentialSelf-citationSynergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798
Self-citationTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“TREM2 variants seem to cause loss of function of TREM2 and reduce the ability of microglia to respond to toxic metabolites and clear them from the brain.(21) Although initial studies examining”
BackgroundSuárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
Self-citation
Research works printed but not linked: 1
- Palmqvist, 2019, Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease, EMBO Mol Med, 11, e11170, 10.15252/emmm.201911170 · DOI · Paper page
Cited by
Items 601–660 of 660
Novel cell markers with altered expression in brain aging and Alzheimer's disease: A review
Alobu, E. J., Uchewa, O. O., & Ibegbu, A. O. (2026) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2026.08.010
Tan, J., Wang, K., Song, H., Zhang, N., & Lin, Z. J. (2026) · NeuroMarkers. · doi:10.1016/j.neumar.2026.100235
Abrahamson, E. E., Kofler, J. K., López, O. L., Cohen, A. D., Gogola, A., Aizenstein, H. J., Karikari, T. K., Mufson, E. J., Villemange, V., & Ikonomović, M. D. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71685
Rizvi, B. M., Maillard, P., Posis, A. I. B., Colbeth, H., Chen, N. X., Brickman, A. M., Gilsanz, P., Corrada, M. M., & Whitmer, R. A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71795
Fischer, L., Vockert, N., Fernandes, J. H., Garcia‐Garcia, B., Roemer, S. N., Franzmeier, N., Gellersen, H. M., Schumann‐Werner, B., Behrenbruch, N., Schwarck, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.18.745399
Alsulami, A., Moreno, J. A., Montrose, L., Nordgren, T., LaRocca, T. J., & McGrath, S. (2026) · doi:10.25675/3.027441
Ohara, K., Zhang, H., Shibata, H., & Hasegawa, Y. (2026) · Journal of Dietary Supplements · doi:10.1080/19390211.2026.2718077
Diagnosticar antes dos sintomas: marcadores precoces da doença de Alzheimer na fase pré-clínica
Fontes, L. S., PINTO, J. L. S. D. D. N., Napoleão, R. M. D. S., Oliveira, H. A., & Botelho, A. M. P. (2026) · Aposta · doi:10.23900/ra.v24i118.1857
Zhao, W., Zhu, M. Y., Patel, H., Whitson, H. E., Johnson, K. G., Grewal, D. S., & Fekrat, S. (2026) · Diagnostics · doi:10.3390/diagnostics16172764
Zhang, S., Bao, R., He, H., Initiative, A. D. N., The Health and Aging Brain Study (HABS‐HD) Study Team, Zhang, T., Cheng, W., & Ding, W. (2026) · Research Square · doi:10.21203/rs.3.rs-10847343/v1
Ding, S., Yang, J., Wang, Z., Bai, R., Yin, K., Jin, L., Kueckelhaus, M., Meuth, S. G., Xiao, M., & Hu, G. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00579-9
Fayisa, D. K., Faizan, M., Wu, W.-C., Chen, J.-K., & Liu, C. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.120229
Haskins, W. E., Wang, K., Cai, G., Boukholda, K., Elbayoumi, E., Bajpai, R., Jackson, D., Tehas, K., Radeker, K., DeLizza, A., et al. (2026) · medRxiv · doi:10.64898/2026.09.01.26361845
Wu, F., & Wang, M. (2026) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlag098
Han, W., Li, N., Wang, P., An, W., Han, X., An, Y., & Initiative, A. D. N. (2026) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70475
A Trust-Network-Based Federated Learning Framework for Multi-Center Aging Clock PredictionPreprint
Zhang, C., Li, B., Wang, W., Liu, Y., Jiang, D., Huang, Y., Nabeshima, Y.-I., YAMAMURA, A., Yang, B., & Yang, Q. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2609.10108
Agnello, L., Gambino, C. M., Salemi, G., Stefano, V. D., Piccoli, T., Masucci, A., Novara, S., Ciaccio, A. M., Ben, F. D., Capello, D., et al. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70690
Plasma proteomics reveals stage-dependent biological remodelling in Alzheimer’s diseasePreprint
Gu, Y., Kim, J. P., Kim, B. H., Lee, H., Lee, J., Kang, H., Yim, S., Shin, D., Park, H. K., Kim, S., et al. (2026) · medRxiv · doi:10.64898/2026.09.14.26362968
Self-citationSchwarck, S., Behrenbruch, N., Schumann‐Werner, B., Molloy, E. N., Garcia‐Garcia, B., Hochkeppler, A., Fischer, L., Büchel, A., Incesoy, E. I., Bernal, J., et al. (2026) · npj Aging · doi:10.1038/s41514-026-00512-4
Jahanbin, K., & Initiative, A. D. N. (2026) · FASEB BioAdvances · doi:10.1096/fba.2026-00194
Wang, Z., Liu, Y., Sun, X., & Ling, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1948518
Alruwaili, M., Turkistani, A. A., Shilbayeh, S. A. R., Mirdad, D. S. A., Almulhim, M. F., Alnaaim, S., Almubarak, M., & Initiative, A. D. N. (2026) · Immunologic Research · doi:10.1007/s12026-026-09848-1
Huang, Y., Toga, A. W., Zhao, L., & Initiative, T. A. D. N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.17.752468
Poimenova, I. A., Mikheev, I. V., Manuilenko, V. A., Proskurnina, E. V., & Proskurnin, М. А. (2026) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2026.2738019
DOENÇA DE ALZHEIMER: AVANÇOS NO DIAGNÓSTICO PRECOCE, BIOMARCADORES E PERSPECTIVAS TERAPÊUTICAS
Moreira, A. C. B., Martins, T. K. C., Freitas, V. L. H., & Neto, T. F. (2026) · Asclepius International Journal of Scientific Health Science · doi:10.70779/aijshs.v5i9.697
Utilidad del diagnóstico precoz de enfermedad de Alzheimer con biomarcadores en plasma
Lamoth, E. B., Larrarte, J. P. M., Abreu, S. M. P., Hernández, E. F., & Rojas, Y. G. M. (2025) · Revista Cubana de Reumatología: RCuR
GFAP Use in Emergency Medicine—A Narrative Review
Ghazala, M. T., Sula, I., Jihwaprani, M. C., Aljabri, A. H., Saif, S. Y., Alhebshi, A., Alatae, H. G., & Hassan, A. E.-S. (2026) · NeuroSci · doi:10.3390/neurosci7050108
An 11‐Protein Plasma Proteomic Signature Associated With Incident Dementia Risk in the UK Biobank
Yang, S., Wang, Z., Wu, Y., Feng, H., Yang, Z., & Yang, Y. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70854
Mesquita, V. A., Arze, B. B. D. O., Linhares, N. J. D. O., Madeira, C. S., de Freitas, T. L., Santos, F. S. D., Júnior, H. D. S. E. S., Moreno, A. M., & Orsini, M. A. (2026) · Revista brasileira de neurologia · doi:10.46979/rbn.v62i3.72687
Benign multiple sclerosis, aspects of neurodegeneration with soluble biomarkers and MRI imaging
Niiranen, M. (2024) · UEF eRepo (University of Eastern Finland)
Astrocyte Structure–Function Relationship in Senescence and Neurodegeneration
Serebryanaya, D. V., Kolgaeva, K. A., Dya, G. A., Ermakov, I. M., & Belousov, V. V. (2026) · Biochemistry (Moscow) · doi:10.1134/s000629792660208x
Alsulami, A., Bogdani, M., MacLean, E. L., Keene, C. D., McGrath, S., Akey, J. M., Benton, B., Borenstein, E., Castelhano, M. G., Coleman, A. E., et al. (2026) · npj Dementia · doi:10.1038/s44400-026-00141-4
Bianco, C., Rabaneda‐Lombarte, N., Fatima, H., Celedón, J., Oakley, D. H., Arnold, S. E., Kivisäkk, P., & Serrano‐Pozo, A. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71883
Advances in non-invasive monitoring of drug delivery for neurodegenerative disorders
Choi, J. Y., & Heiss, J. D. (2026) · Expert Review of Medical Devices · doi:10.1080/17434440.2026.2743929
EMERGING BLOOD-BASED BIOMARKERS IN ALZHEIMER’S DISEASE: FOCUS ON TAU, NFL, AND GFAP
Turabi, S. (2026) · Indian Journal of Health Care Medical & Pharmacy Practice · doi:10.59551/ijhmp/25832069/2026.7.2.140
Li, X. (2026) · Clinical Interventions in Aging · doi:10.2147/cia.s641221
Zhang, K., Zhang, Y., Jiang, X., & Chen, X. (2026) · Aging and Disease · doi:10.14336/ad.2026.0888
Ding, L., Zheng, M., Wang, S., Liu, W., Liang, Y., Xie, S., Yang, T., Sheng, D., Wang, S., Sheng, J., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71915
Zhao, P., Lai, S., Dai, S., Zhou, C., Li, N., & Yu, W. (2026) · Biomedicines · doi:10.3390/biomedicines14102342
Midlife and Late-Life Alzheimer Disease Blood Biomarkers and 11-Year Cognitive Decline
Smith, J. R., Pike, J. R., Lü, Y., Walker, K. A., Sullivan, K., Windham, B. G., Thyagarajan, B., Mielke, M. M., Lutsey, P. L., Hughes, T. M., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000218692
Ho, S. G., Shen, Z., Lewis, A., Patel, M., Zheng, A., Proscino, G., Ho, T., Wang, J., Albert, M., & Moghekar, A. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70524
Integration of neuroimaging signatures of aging and Alzheimer's with fluid biomarkers
Gonzales, M. M., Ho, N. H., Wang, D. H., Rashid, T., Brandigampala, S. R., Dong, M., Martinez, D., Charisis, S., Hohman, T. J., Seshadri, S. S., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71889
Huang, Y., Huang, L., Cui, L., Pan, F., Xie, F., Guo, H., Guo, Q., & Initiative, F. T. A. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71922
Perneczky, R., Schöll, M., Rauchmann, B., & Hofmann, A. (2026) · Neuron · doi:10.1016/j.neuron.2026.09.006
APOE ε4 accelerates plasma p-tau217 trajectory: a Bayesian joint longitudinal analysis of ADNI
Chu, K.-Y. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09435-0
Dema, A., Dan, T. F., Copil, A., & Jianu, D. C. (2026) · Biomedicines · doi:10.3390/biomedicines14112451
Impact of post-translational modifications in Alzheimer’s disease: An overview
Venkataramaiah, C. (2026) · Current Proteomics · doi:10.1016/j.curpro.2026.100189
Blood-based biomarkers across the Alzheimer’s disease continuum in older Korean populationPreprint
Kang, S., Choi, Y. Y., Kim, M., Choi, K. Y., Seo, E. H., Hwang, H., Chung, J. Y., Kim, J., Song, H.-C., Kim, H., et al. (2026) · medRxiv · doi:10.64898/2026.10.27.26366659
Abdolmaleki, M., Gaynor, L. S., Liu, D., Hohman, T. J., Gifford, K. A., Zetterberg, H., Jefferson, A. L., & Bolton, C. J. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70565
Self-citationFeng, J., Huang, X., Shi, Y., Gao, Y., Chen, J., Song, Z., Mao, X., Niu, S., Li, J., & Li, J. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1987345
Glial Cell Mechanisms in Alzheimer’s Disease Pathology and Progress in Biomarker Research
Li, L., Zhang, Y.-B., Zhang, R.-Z., Wen-ting, X., Wang, Y., Ya-ru, Z., Wei, Y.-T., Ma, C., & Yan, X.-K. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s646472
Harun‐Ur‐Rashid, M., & Jahan, I. (2026) · Aging Pathobiology and Therapeutics · doi:10.31491/apt.2026.09.230
Stage–Specific Roles of Plasma GFAP in Linking Amyloid Cascade in Alzheimer DiseasePreprint
Niu, X., 孙秋昌, Wisch, J. K., Jiang, M., Luna, A., Hoagey, D. A., Schindler, S. E., Cruchaga, C., Gordon, B. A., Wang, Y., et al. (2026) · medRxiv · doi:10.64898/2026.11.03.26366374
Developing the World‐Wide FINGERS biorepository for dementia risk reduction trials
Matton, A., Udeh‐Momoh, C. T., Daniilidou, M., Bereczki, E., Alanko, V., Padilla, P., Baker, L. D., Ban, K., Borda, M. G., Caramelli, P., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71949
Self-citationCai, Y., Miao, J., Gogniat, M. A., Snitz, B. E., & Cohen, A. D. (2026) · GeroScience · doi:10.1007/s11357-026-02645-6
Chakraborty, W., & Roy, K. K. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06313-w
Beat-to-beat blood pressure variability and Alzheimer’s disease pathophysiologyPreprint
Lohman, T., Joyce, J. L., Quiring, M. L., Lashin, B. I., Kapoor, A., Engstrom, A. C., Law, K., Ferrer, F., Contreras, L., Alitin, J. P., et al. (2026) · medRxiv · doi:10.64898/2026.11.10.26367476
Yu, D. (2024) · TSpace (University of Toronto)
Shang, L., Dong, L., Xinying Huang, Wang, T., Mao, C., Li, J., Wang, J., Liu, C., & Gao, J. (2023) · doi:10.3389/fnagi.2023.1119070.s001
Metadata
- Authors
- Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., & Hansson, O.
- Affiliations
- Lund University (SE)
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sweden
- Amsterdam Neuroscience (NL)
- Sahlgrenska University Hospital (SE)
- King's College London (GB)
- Corresponding author
- Pereira, Joana B
- Hansson, Oskar
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-02
- Volume
- 144
- Issue
- 11
- Pages
- 3505-3516
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC8677538
- OpenAlex
- W3182927843
- Cited by
- 598
- References
- 61
- Citations by year
- 2026: 148 · 2025: 140 · 2024: 141 · 2023: 92 · 2022: 66 · 2021: 10
- FWCI
- 48.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Swedish Research Council (2016–00906, 2018–02052, #2018–02201, #2017–00915, #2018–02532)
- Knut and Alice Wallenberg foundation (2017–0383)
- Marianne and Marcus Wallenberg foundation (2015.0125)
- Strategic Research Area MultiPark
- Swedish Alzheimer Foundation (AF-939932, #AF-742881)
- Swedish Brain Foundation (FO2019-0326)
- The Parkinson foundation of Sweden (1280/20)
- Skåne University Hospital Foundation (2020-O000028)
- Regionalt Forskningsstöd (2020–0314)
- Swedish federal government (2018-Projekt0279)
- The Center for Medical Innovation (#20200695)
- Karolinska Institute
- Alzheimer Drug Discovery Foundation (#RDAPB-201809–2016615)
- Hjärnfonden, Sweden (#FO2017-0243)
- ALF (#ALFGBG-715986)
- European Union Joint Program for Neurodegenerative Disorders (JPND2019-466–236)
- European Research Council (#681712)
- Swedish State Support for Clinical Research (#ALFGBG-720931)
- UK Dementia Research Institute
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, tau pathology, astrocyte activation, astroglial activation, biomarkers, cerebrospinal fluid biomarkers, amyloid PET, tau PET, 18F-flutemetamol, cognitive impairment
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Glial Fibrillary Acidic Protein, Humans, Male, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.